Search Results
295 results
Your search is now limited to «Johnson & Johnson» expert search.
STAT 03/22/2019 13:06
With a potential annual tab running from $33,000 to $49,200, a preliminary analysis says J&J's esketamine fails to provide sufficient value.
More from STAT:
BioPharma Dive 03/22/2019 09:14
Last year, J&J ended mid-stage clinical testing on the compound after taking a $630 million after-tax charge.
More from BioPharma Dive:
Business Standard (India) 03/21/2019 23:08
J&J had recorded a partial impairment charge of about $630 million related to the treatment in the third quarter last year after having suspended trials in August.
More from Business Standard (India):
ENDPOINTS 03/21/2019 21:12
Back in the fall of 2014, Alios looked like quite a find for J&J, with its lead RSV drug and some early stage hep C programs as a group of rivals fought over the blockbuster market that awaited the winner of that contest.
More from ENDPOINTS:
FirstPost (India) 03/21/2019 18:35
(Reuters) - Johnson & Johnson on Thursday said https://www.sec.gov/Archives/edgar/data/200406/000020040619000/a20190321alios8-k.htm it will record a nearly $700 million impairment charge in the first quarter of 2019 related to the abandoned development of its experimental antiviral drug, AL-8176. The post J&J to record $700 million charge related to abandoned drug program appeared first on Firstpost .
More from FirstPost (India):
Channel NewsAsia (Singapore) 03/21/2019 18:26
Johnson & Johnson on Thursday said it will record a nearly US$700 million impairment charge in the first quarter of 2019 related to the abandoned development of its experimental antiviral drug, AL-8176.
More from Channel NewsAsia (Singapore):
Pharmafile 03/21/2019 06:22
Johnson & Johnson has announced it is to end its practice of forced swim tests on mice, rats and other animals in the research of new drug treatments, following discussion with animal rights advocacy group PETA. The company’s pledge means it will not use the test from now on in either its own or external laboratories. Forced swimming tests – or behavioural despair tests, as they are also known – involve placing a mouse or rat in an acrylic cylinder from which they cannot escape as it slowly fills with water. read more.
More from Pharmafile:
MassDevice 03/19/2019 17:03
FDA warns J&J, Sientra over lack of post-approval silicone gel breast implant studies.
More from MassDevice:
MedicalDeviceLink.com 03/19/2019 16:34
FDA busted two manufacturers of silicone gel-filled breast implants this week for failure to comply with post-approval study requirements. The agency sent warning letters to Irvine, CA-based Mentor Worldwide, a unit of Johnson & Johnson, and to Santa Barbara, CA-based Sientra for deficiencies in each company's post-approval study for silicone breast implant approvals. FDA noted that every manufacturer of FDA-approved silicone gel-filled breast implants has to conduct post-approval studies to further evaluate safety and effectiveness of the products and to answer additional scientific questions about the long-term safety and potential risks of breast implants that their premarket clinical trials were not designed to answer. “Post-approval r.
More from MedicalDeviceLink.com:
PR Newswire 03/19/2019 08:08
WAYNE, Pa., March 19, 2019 /PRNewswire/ -- Moro Corporation (NQB: MRCR), a multi-subsidiary construction products and services company, today announced the exciting addition of Revit software, a cutting-edge building information modeling platform, at subsidiary J&J Sheet Metal.
More from PR Newswire:
Zacks.com 03/18/2019 09:01
Meanwhile, the FDA granted a 10-month review period to Allergan’s regulatory application for key pipeline candidate ubrogepant while J&J filed an application with the same authority looking for approval of its multiple myeloma drug , Darzalex in an expanded patient population.
More from Zacks.com:
Top Class Actions 03/18/2019 07:00
Tobias said that the elimination of Imerys from the cancer lawsuit “really puts J&J more in the crosshairs for all of these cases.
More from Top Class Actions:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications